Incyte Faces Limited Exposure From Tariffs on Dual Sourcing, UBS Says

MT Newswires Live2025-04-11

Incyte (INCY) faces limited exposure to tariffs with dual sourcing for key products in the Europe and US, UBS said Wednesday in a report.

The large molecule production facility is in Switzerland, combined with investments in US manufacturing capacity, leaves Incyte "relatively less exposed to policy and

regulatory risks weighing on the rest of the biopharma sector," the report said.

UBS estimated Q1 sales of $103 million on Opzelura, used to treat atopic dermatitis, trailing the consensus forecast of $131 million. The bank's projection on Jakafi, containing ruxolitinib used to treat certain blood cancers, rose to $640 million from $606 million, compared with the consensus $643 million.

Results from Q1 are expected April 29.

UBS maintained its neutral rating on Incyte stock and reduced the price target to $61 from $69, partly citing "a lack of meaningful pipeline catalysts."

Incyte shares fell 5.3% in recent Thursday trading.

Price: 55.72, Change: -3.14, Percent Change: -5.33

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2526453125?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-11 03:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2526453125","market":"fut","top_or_hot":-1,"title":"Incyte Faces Limited Exposure From Tariffs on Dual Sourcing, UBS Says","media":"MT Newswires Live","content":"<html><body><p> Incyte (INCY) faces limited exposure to tariffs with dual sourcing for key products in the Europe and US, UBS said Wednesday in a report.</p><p>The large molecule production facility is in Switzerland, combined with investments in US manufacturing capacity, leaves Incyte \"relatively less exposed to policy and</p><p>regulatory risks weighing on the rest of the biopharma sector,\" the report said.</p><p>UBS estimated Q1 sales of $103 million on Opzelura, used to treat atopic dermatitis, trailing the consensus forecast of $131 million. The bank's projection on Jakafi, containing ruxolitinib used to treat certain blood cancers, rose to $640 million from $606 million, compared with the consensus $643 million.</p><p>Results from Q1 are expected April 29.</p><p>UBS maintained its neutral rating on Incyte stock and reduced the price target to $61 from $69, partly citing \"a lack of meaningful pipeline catalysts.\"</p><p>Incyte shares fell 5.3% in recent Thursday trading.</p><p>Price: 55.72, Change: -3.14, Percent Change: -5.33</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte Faces Limited Exposure From Tariffs on Dual Sourcing, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte Faces Limited Exposure From Tariffs on Dual Sourcing, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-11 03:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Incyte (INCY) faces limited exposure to tariffs with dual sourcing for key products in the Europe and US, UBS said Wednesday in a report.</p><p>The large molecule production facility is in Switzerland, combined with investments in US manufacturing capacity, leaves Incyte \"relatively less exposed to policy and</p><p>regulatory risks weighing on the rest of the biopharma sector,\" the report said.</p><p>UBS estimated Q1 sales of $103 million on Opzelura, used to treat atopic dermatitis, trailing the consensus forecast of $131 million. The bank's projection on Jakafi, containing ruxolitinib used to treat certain blood cancers, rose to $640 million from $606 million, compared with the consensus $643 million.</p><p>Results from Q1 are expected April 29.</p><p>UBS maintained its neutral rating on Incyte stock and reduced the price target to $61 from $69, partly citing \"a lack of meaningful pipeline catalysts.\"</p><p>Incyte shares fell 5.3% in recent Thursday trading.</p><p>Price: 55.72, Change: -3.14, Percent Change: -5.33</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2526453125","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2526453125","pubTimestamp":1744313124,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Incyte  faces limited exposure to tariffs with dual sourcing for key products in the Europe and US, UBS said Wednesday in a report.The large molecule production facility is in Switzerland, combined with investments in US manufacturing capacity, leaves Incyte \"relatively less exposed to policy andregulatory risks weighing on the rest of the biopharma sector,\" the report said.UBS estimated Q1 sales of $103 million on Opzelura, used to treat atopic dermatitis, trailing the consensus forecast of $131 million. The bank's projection on Jakafi, containing ruxolitinib used to treat certain blood cancers, rose to $640 million from $606 million, compared with the consensus $643 million.Results from Q1 are expected April 29.UBS maintained its neutral rating on Incyte stock and reduced the price target to $61 from $69, partly citing \"a lack of meaningful pipeline catalysts.\"Incyte shares fell 5.3% in recent Thursday trading.Price: 55.72, Change: -3.14, Percent Change: -5.33","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4550":"红杉资本持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","INCY":"因塞特医疗"},"translate_title":"瑞银表示，Incyte面临的双重采购关税风险有限","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":1},"content_text":"Incyte (INCY) faces limited exposure to tariffs with dual sourcing for key products in the Europe and US, UBS said Wednesday in a report.The large molecule production facility is in Switzerland, combined with investments in US manufacturing capacity, leaves Incyte \"relatively less exposed to policy andregulatory risks weighing on the rest of the biopharma sector,\" the report said.UBS estimated Q1 sales of $103 million on Opzelura, used to treat atopic dermatitis, trailing the consensus forecast of $131 million. The bank's projection on Jakafi, containing ruxolitinib used to treat certain blood cancers, rose to $640 million from $606 million, compared with the consensus $643 million.Results from Q1 are expected April 29.UBS maintained its neutral rating on Incyte stock and reduced the price target to $61 from $69, partly citing \"a lack of meaningful pipeline catalysts.\"Incyte shares fell 5.3% in recent Thursday trading.Price: 55.72, Change: -3.14, Percent Change: -5.33","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2526453125","isCrawlerRequest":true}